ClinicalTrials.gg
RecruitingNCT05596526MSHINGVAXUpdated Apr 10, 2024

Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

A Phase 4 interventional study of recombinant zoster vaccine in Shingles and Zoster, sponsored by Prof Patrice Lalive. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-10.

Sponsored by Prof Patrice Lalive · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Planned enrollment
34th of 46
100 · median 239
Started
2022
with 2 others
Phase 4
8 of 46
4 open now
Primary completion
2024-12
later than 0 of 10 live
Registered
38th of 46
by date

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 34th largest by planned enrollment, is one of 3 that started in 2022, is one of 8 in phase 4, reaches primary completion later than 0 of the 10 other live ones, and was the 38th registered.

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.

Read the detailed description

In this monocentric study, we will assess the immunogenicity and safety of two doses of the adjuvanted recombinant Zoster vaccine (RZV, or Shingrix®) in Multiple sclerosis patients treated with anti-CD20 (ocrelizumab, group 1) compared to healthy controls (group 2).

Participants will receive Shingrix® on Day0 and Day60; immunological response will be assessed on Day 0, 1, Day 60, 61, Day90 and Day360.

Unsolicited Adverse events of special interest (AESI) will be collected throughout the study period; patients reported outcomes (PROs) will be declared for one week after each vaccination. Safety of MS patients will be monitored through EDSS scoring and MRI before and 1 month after vaccination (D90) and at day 180 and 360 (EDSS scoring only)

03

Conditions studied

  • Shingles
  • Zoster

Keywords

  • RZV vaccine
  • Multiple Sclerosis
  • Immune response
  • Safety
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For MS patients:

  • 18 years and above
  • Diagnosed with relapsing MS according to McDonald Criteria (2017)
  • Not already vaccinated by RZV and willing to be vaccinated with RZV.
  • At least 1 year on anti-CD20 treatment: 2 initial infusions of Ocrelizumab 300 mg (2 weeks apart), one infusion of Ocrelizumab 600 mg 6 months apart, one infusion of Ocrelizumab 600 mg 12 months after initial infusions
  • as documented by signature

For healthy controls

  • Aged 50 to 59
  • Not already vaccinated by RZV and willing to be vaccinated with RZV
  • Informed consent as documented by signature

Exclusion criteria

Exclusion Criteria:

  • Recent MS relapse in the 6 weeks preceding planned vaccination
  • Ongoing signs of febrile or non-febrile infection at the time of vaccination
  • Recent pregnancy with delivery in the six months preceding vaccination and/or planned pregnancy in the six months following RZV vaccination
  • from the following: infection, current active systemic auto-immune disease (other than MS), current malignant neoplasm; primary immunodeficiency; recent solid or bone-marrow transplant or any transplant still requiring immunosuppressive therapy; conditions requiring medication with immunosuppressive drugs
  • Having received a vaccine in the last month
  • Having received a shingles vaccine within one year
  • Presented with herpes zoster in the previous year
  • to RZV
  • Unable to provide or inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia.
  • Participation in another study with drug within the 30 days preceding and during the present study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    MS patients on anti-CD20

    Participants aged 18 and above will receive two doses of the recombinant Zoster vaccine (Shingrix®)

    Biological: recombinant zoster vaccine

  • Experimental
    Healthy controls

    Healthy participants aged 50 to 59 will receive two doses of the recombinant Zoster vaccine (Shingrix®)

    Biological: recombinant zoster vaccine

Interventions

  • BiologicalShingrixStudies of ShingrixShingrix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60

    Also known as: Shingrix®

06

What researchers measure

Primary outcomes

  1. Geometric mean titer (GMT) of glycoprotein E (gE)-specific total IgG

    gE-specific total Immunoglobulin(Ig)G titers is determined by gE-specific ELISA from sera samples

    Time frame: day 90

Secondary outcomes

  1. Vaccine safety - AESI 7 days

    Incidence adverse events of special interest (AESI) in the 7 days following each vaccination (reactogenicity) collected in a diary card

    Time frame: 7 days

  2. Vaccine safety - SAE 360 days

    Incidence of serious adverse events (SAE) throughout the study period

    Time frame: day 360

  3. Vaccine safety -pIMDs

    Incidence of potential immune mediated disorders (pIMDs) throughout the study period

    Time frame: day 360

  4. Vaccine safety-relapse in MS patients

    Incidence of relapse in MS patients during a follow-up of 3 months after the first dose (d90) compared to the year preceding vaccination with RZV

    Time frame: day 90

  5. Vaccine immunogenicity - CD4+ T cells per million of T cells, measured at D90

    Mean of gE-specific CD4+ T cells expressing at least 2 activation markers (i.e. CD40 ligand, interferon-gamma, IL-2 or TNF-alpha) per million of T cells, measured at D90

    Time frame: Day 90

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2024, 24 months after the start.

Of 19 phase 4 interventional studies under Herpes Zoster, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2022
First posted
Oct 27, 2022
StartActual
Dec 1, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Apr 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05596526
Lead sponsor
Prof Patrice Lalive
Responsible party
Prof Patrice Lalive (Professor, University Hospital, Geneva) — Sponsor-investigator
First posted
Oct 27, 2022
Start date
Dec 1, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 10, 2024

Study contacts

Arnaud Didierlaurent, Pr
Contact
arnaud.didierlaurent@hcuge.ch
+41 22 37 95781
Patrice Lalive, Pr
Contact
patrice.lalive@hcuge.ch
+41 22 3728318
Patrice Lalive, Pr
principal investigator · University Hospitals of Geneva
Arnaud Didierlaurent, Pr
study director · University Hospitals of Geneva

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion